An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Completed · Phase 3 · Has a placebo group

Conditions studied: Migraine, With or Without Aura

In brief

This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

Key facts

Study ID
NCT02873221
Run by
Allergan
People needed
1254
Starts
2016-09-13
Expected to finish
2018-08-02
Last updated by the study team
2019-08-28

Who can join

Age: 18 and older, up to 76. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.